<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
Ilex Oncology, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
0004519231
-----------------------------------------
(CUSIP Number)
- -------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/ / Rule 13d-1(c)
/X/ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
- -------------------- ------------------
CUSIP NO. 0004519231 13G PAGE 2 OF 14 PAGES
- -------------------- ------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Cross Atlantic Partners K/S II
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) / /
(b) / /
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Denmark
- -------------------------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
- -------------------------------------------------------------------------------
5 SOLE VOTING POWER
0 Shares
----------------------------------------------------
6 SHARED VOTING POWER
575,836 Shares
----------------------------------------------------
7 SOLE DISPOSITIVE POWER
0 Shares
----------------------------------------------------
8 SHARED DISPOSITIVE POWER
575,836 Shares
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
575,836 Shares
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) / /
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.5%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
- -------------------------------------------------------------------------------
Page 2 of 14 Pages
<PAGE>
- -------------------- ------------------
CUSIP NO. 0004519231 13G PAGE 3 OF 14 PAGES
- -------------------- ------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Cross Atlantic Partners K/S
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) / /
(b) / /
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Denmark
- -------------------------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
- -------------------------------------------------------------------------------
5 SOLE VOTING POWER
0 Shares
----------------------------------------------------
6 SHARED VOTING POWER
575,836 Shares
----------------------------------------------------
7 SOLE DISPOSITIVE POWER
0 Shares
----------------------------------------------------
8 SHARED DISPOSITIVE POWER
575,836 Shares
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
575,836 Shares
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) / /
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.5%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
- -------------------------------------------------------------------------------
Page 3 of 14 Pages
<PAGE>
- -------------------- ------------------
CUSIP NO. 0004519231 13G PAGE 4 OF 14 PAGES
- -------------------- ------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
CAP/Hambro, L.P.
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) / /
(b) / /
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Denmark
- -------------------------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
- -------------------------------------------------------------------------------
5 SOLE VOTING POWER
0 Shares
----------------------------------------------------
6 SHARED VOTING POWER
575,836 Shares
----------------------------------------------------
7 SOLE DISPOSITIVE POWER
0 Shares
----------------------------------------------------
8 SHARED DISPOSITIVE POWER
575,836 Shares
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
575,836 Shares
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) / /
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.5%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
PN
- -------------------------------------------------------------------------------
Page 4 of 14 Pages
<PAGE>
- -------------------- ------------------
CUSIP NO. 0004519231 13G PAGE 5 OF 14 PAGES
- -------------------- ------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
CAP/Hambro, Inc.
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) / /
(b) / /
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Denmark
- -------------------------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
- -------------------------------------------------------------------------------
5 SOLE VOTING POWER
0 Shares
----------------------------------------------------
6 SHARED VOTING POWER
575,836 Shares
----------------------------------------------------
7 SOLE DISPOSITIVE POWER
0 Shares
----------------------------------------------------
8 SHARED DISPOSITIVE POWER
575,836 Shares
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
575,836 Shares
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) / /
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.5%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- -------------------------------------------------------------------------------
Page 5 of 14 Pages
<PAGE>
- -------------------- ------------------
CUSIP NO. 0004519231 13G PAGE 6 OF 14 PAGES
- -------------------- ------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Hambro America Private Equity, Inc. (f/k/a Hambro America, Inc.)
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) / /
(b) / /
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Denmark
- -------------------------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
- -------------------------------------------------------------------------------
5 SOLE VOTING POWER
0 Shares
----------------------------------------------------
6 SHARED VOTING POWER
575,836 Shares
----------------------------------------------------
7 SOLE DISPOSITIVE POWER
0 Shares
----------------------------------------------------
8 SHARED DISPOSITIVE POWER
575,836 Shares
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
575,836 Shares
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS) / /
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.5%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- -------------------------------------------------------------------------------
Page 6 of 14 Pages
<PAGE>
NOTE: This Statement on Schedule 13G is being filed on behalf of Cross
Atlantic Partners K/S, Cross Atlantic Partners K/S II,
CAP/Hambro, L.P., CAP/Hambro, Inc. and Hambro America Private
Equity, Inc. (f/k/a Hambro America, Inc.). CAP/Hambro, L.P. is
the sole general partner of Cross Atlantic Partners, K/S and
Cross Atlantic Partners K/S II. CAP/Hambro, Inc. is the sole
general partner of CAP/Hambro, L.P. Hambro America Private
Equity, Inc. (f/k/a Hambro America, Inc.) is the sole shareholder
of CAP/Hambro, Inc.
Item 1(a). NAME OF ISSUER: Ilex Oncology, Inc.
Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 11550
IH-10 West Suite 300 San Antonio, TX 78230
<TABLE>
<CAPTION>
Item 2(a) Item 2(b) Item 2(c)
--------- --------- ---------
Citizenship or Place
Name of Person Filing Address of Organization
--------------------- ------- --------------------
<S> <C> <C>
Cross Atlantic Partners K/S, a Danish c/o Hambro Health International, Inc. Denmark
limited partnership 650 Madison Avenue
New York, NY 10022
Cross Atlantic Partners K/S II, a c/o Hambro Health International, Inc. Denmark
Danish limited partnership 650 Madison Avenue
New York, NY 10022
CAP/Hambro, L.P., the sole general c/o Hambro Health International, Inc. Delaware
partner of Cross Atlantic 650 Madison Avenue
Partners K/S and Cross Atlantic New York, NY 10022
Partners K/S II
CAP/Hambro, Inc., the sole general c/o Hambro Health International, Inc. Delaware
partner of CAP/Hambro, L.P., 650 Madison Avenue which is
wholly-owned by Hambro New York, NY 10022
America Private Equity, Inc.
Hambro America Private Equity, Inc. c/o Hambro Health International, Inc. New York
(f/k/a Hambro America, Inc.), 650 Madison Avenue
the parent corporation of New York, NY 10022
CAP/Hambro, Inc.
</TABLE>
Item 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, $.01 par value.
Item 2(e). CUSIP NUMBER: 0004519231
Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13D-1(B), OR
13D-2(B), CHECK WHETHER THE PERSON FILING IS A:
(a) // Broker or Dealer registered under Section 15 of the
Securities Exchange Act of 1934 (the "Act").
(b) // Bank as defined in Section 3(a)(6) of the Act.
(c) // Insurance Company as defined in Section 3(a)(19) of the
Act.
(d) // Investment Company registered under Section 8 of the
Investment Company Act of 1940.
(e) // An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
(f) // An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F);
Page 7 of 13 Pages
<PAGE>
(g) // A parent holding company or control person in
accordance with Rule 13d-1(b)(1)(ii)(G);
(h) // A savings association as defined in Section 3(b)
of the Federal Deposit Insurance Act;
(i) // A church plan that is excluded from the definition of
an investment company under Section 3(c)(14) of the
Investment Company Act;
(j) // Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
If this statement is filed pursuant to Rule 13d-1(c), check this
box.
None of the above.
Item 4. OWNERSHIP.
(a) Amount Beneficially Owned: As of December 31, 1998, each of
the following is the owner of record of the number of shares
of Common Stock set forth next to its name:
<TABLE>
<CAPTION>
<S> <C>
Cross Atlantic Partners K/S 554,849 shares
Cross Atlantic Partners K/S II 20,987 shares
CAP/Hambro, L.P. 0 shares
CAP/Hambro, Inc. 0 shares
Hambro America Private Equity, Inc. 0 shares
(f/k/a Hambro America, Inc.)
</TABLE>
Additionally, Cross Atlantic Partners K/S and Cross Atlantic
Partners K/S II hold presently exerciseable warrants to purchase
15,468 shares and 9,084 shares, respectively, of Common Stock.
Therefore, CAP/Hambro L.P., CAP/Hambro, Inc., and Hambro America
Private Equity, Inc. (f/k/a Hambro America, Inc.) (collectively
the "Entities") may be deemed to beneficially own the 600,388
shares and exerciseable warrants owned by Cross Atlantic Partners
K/S and Cross Atlantic Partners K/S II. Hence Cross Atlantic
Partners K/S, Cross Atlantic Partners K/S II and the Entities may
be deemed to own beneficially an aggregate of 600,388 shares
(Common Stock and Warrants) as of December 31, 1998.
(b) Percent of Class:
<TABLE>
<S> <C>
Cross Atlantic Partners K/S 4.5%
Cross Atlantic Partners K/S II 4.5%
CAP/Hambro, L.P. 4.5%
CAP/Hambro, Inc. 4.5%
Hambro America Private Equity, Inc. 4.5%
(f/k/a Hambro America, Inc.)
</TABLE>
The foregoing percentages are calculated based on the 12,650,738
shares of Common Stock reported to be outstanding in the
Quarterly Report on Form 10-Q of Ilex Oncology, Inc. for the
quarter ended September 30, 1998.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
<TABLE>
<S> <C>
Cross Atlantic Partners K/S 0 shares
Cross Atlantic Partners K/S II 0 shares
CAP/Hambro, L.P. 0 shares
CAP/Hambro, Inc. 0 shares
Hambro America Private Equity, Inc. 0 shares
(f/k/a Hambro America, Inc.).
</TABLE>
Page 8 of 13 Pages
<PAGE>
(ii) shared power to vote or to direct the vote:
<TABLE>
<S> <C>
Cross Atlantic Partners K/S 575,836 shares
Cross Atlantic Partners K/S II 575,836 shares
CAP/Hambro, L.P. 575,836 shares
CAP/Hambro, Inc. 575,836 shares
Hambro America Private Equity, Inc. 575,836 shares
(f/k/a Hambro America, Inc.)
</TABLE>
(iii) sole power to dispose or to direct the disposition
of:
<TABLE>
<S> <C>
Cross Atlantic Partners K/S 0 shares
Cross Atlantic Partners K/S II 0 shares
CAP/Hambro, L.P. 0 shares
CAP/Hambro, Inc. 0 shares
Hambro America Private Equity, Inc. 0 shares
(f/k/a Hambro America, Inc.)
</TABLE>
(iv) shared power to dispose or to direct the disposition
of:
<TABLE>
<S> <C>
Cross Atlantic Partners K/S 575,836 shares
Cross Atlantic Partners K/S II 575,836 shares
CAP/Hambro, L.P. 575,836 shares
CAP/Hambro, Inc. 575,836 shares
Hambro America Private Equity, Inc. 575,836 shares
(f/k/a Hambro America, Inc.)
</TABLE>
Cross Atlantic Partners K/S, Cross Atlantic Partners K/S II,
CAP/Hambro, L.P., CAP/Hambro, Inc., and Hambro America Private
Equity, Inc. (f/k/a Hambro America, Inc.) expressly disclaim
beneficial ownership of any shares of Common Stock of Ilex
Oncology, Inc., except any shares held directly of record.
Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following: /X/
Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not applicable.
Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY.
Not applicable.
Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable. Cross Atlantic Partners K/S, Cross Atlantic
Partners K/S II, CAP/Hambro, L.P., CAP/Hambro, Inc., and Hambro
America Private Equity, Inc. (f/k/a Hambro America, Inc.)
expressly disclaim membership in a "group" as defined in Rule
13d-1(b)(ii)(H).
Item 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.
Item 10. CERTIFICATION.
Not applicable. This statement on Schedule 13G is not filed
pursuant to Rule 13d-1(b) or Rule 13d-1(c).
Attached as EXHIBIT 1 hereto is a Joint Filing Agreement executed by each of the
filing persons pursuant to Rule 13d-1(f) under Section 13(d) of the Act.
Page 9 of 13 Pages
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of his, her or its knowledge and
belief, each of the undersigned certifies that the information set forth in this
statement is true, complete and correct. We also hereby agree to file this
statement jointly pursuant to the agreement set forth as EXHIBIT 1 hereto.
Dated: June 24, 1999
CROSS ATLANTIC PARTNERS K/S
By: CAP/HAMBRO, L.P.
Its General Partner
By: CAP/HAMBRO, INC.
Its General Partner
By: *
-----------------------------------
Charles L. Dimmler, III
Authorized Officer
CROSS ATLANTIC PARTNERS K/S II
By: CAP/HAMBRO, L.P.
Its General Partner
By: CAP/HAMBRO, INC.
Its General Partner
By: *
-----------------------------------
Charles L. Dimmler, III
Authorized Officer
CAP/HAMBRO, L.P.
By: CAP/HAMBRO, INC.
Its General Partner
By: *
-----------------------------------
Charles L. Dimmler, III
Authorized Officer
CAP/HAMBRO, INC.
By: *
-----------------------------------
David Barnett
Authorized Officer
HAMBRO AMERICA PRIVATE EQUITY, INC.
By: *
-----------------------------------
David Barnett
Authorized Officer
*By: /s/ EDWIN A. GOODMAN
-----------------------------------
Edwin A. Goodman
Attorney-in-fact
* This Schedule 13G was executed by Edwin A. Goodman pursuant to Powers of
Attorney attached hereto as Exhibit 2.
Page 10 of 13 Pages
<PAGE>
EXHIBIT 1
AGREEMENT
Pursuant to Rule 13d-1(f) (1) under the Securities Exchange Act of 1934,
the undersigned hereby agree that only one statement containing the information
required by Schedule 13G need be filed with respect to the ownership by each of
the undersigned of shares of Common Stock of Ilex Oncology, Inc.
This Agreement may be executed in any number of counterparts, each of which
shall be deemed an original.
EXECUTED this 24th day of June, 1999.
CROSS ATLANTIC PARTNERS K/S
By: CAP/HAMBRO, L.P.
Its General Partner
By: CAP/HAMBRO, INC.
Its General Partner
By: *
-----------------------------------
Charles L. Dimmler, III
Authorized Officer
CROSS ATLANTIC PARTNERS K/S II
By: CAP/HAMBRO, L.P.
-----------------------------------
Its General Partner
By: CAP/HAMBRO, INC.
-----------------------------------
Its General Partner
By: *
-----------------------------------
Charles L. Dimmler, III
Authorized Officer
CAP/HAMBRO, L.P.
By: CAP/HAMBRO, INC.
Its General Partner
By: *
-----------------------------------
Charles L. Dimmler, III
Authorized Officer
CAP/HAMBRO, INC.
By: *
-----------------------------------
David Barnett
Authorized Officer
Page 11 of 13 Pages
<PAGE>
HAMBRO AMERICA PRIVATE EQUITY, INC.
By: *
-----------------------------------
David Barnett
Authorized Officer
*By: /s/ Edwin A. Goodman
-----------------------------------
Edwin A. Goodman
Attorney-in-fact
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
* This Agreement was executed by Edwin A. Goodman pursuant to Powers of
Attorney attached hereto as Exhibit 2.
Page 12 of 13 Pages
<PAGE>
Exhibit 2
---------
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below hereby constitutes and appoints Edwin A. Goodman and Lisa C.
Torch, and each of them, with full power to act without the other, his or her
true and lawful attorney-in-fact, with full power of substitution, to sign any
and all instruments, certificates and documents that may be necessary, desirable
or appropriate to be executed on behalf of himself or herself as an individual
or in his or her capacity as a general partner of, or an officer of a general
partner of, CAP/Hambro, L.P., CAP/Hambro, Inc., Hambro America, Inc., Cross
Atlantic Partners K/S, Cross Atlantic Partners K/S II and Cross Atlantic
Partners K/S III, pursuant to Section 13 or 16 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), and any and all regulations promulgated
thereunder, and to file the same, with all exhibits thereto, and any other
documents in connection therewith, with the Securities and Exchange Commission,
and with any other entity when and if such is mandated by the Exchange Act or by
the By-laws of the National Association of Securities Dealers, Inc., granting
unto said attorney-in-fact full power and authority to do and perform each and
every act and thing necessary, desirable or appropriate, fully to all intents
and purposes as he or she might or could do in person, thereby ratifying and
confirming all that said attorney-in-fact, or his substitutes, may lawfully do
or cause to be done by virtue hereto.
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th
day of February, 1998.
/s/ John Cassis
---------------
John Cassis
/s/ Charles L. Dimmler, III
---------------------------
Charles L. Dimmler, III
/s/ David Barnett
-----------------
David Barnett
Page 13 of 13 Pages
